Accession Number:



Safety, Immunogenicity and Lot Stability of the Whole Cell/Recombinant B Subunit (WC/rCTB) Cholera Vaccine in Peruvian Adults and Children

Descriptive Note:

Journal article

Corporate Author:


Report Date:


Pagination or Media Count:



To assess the safety, immunogenicity, and lot stability of the whole cellrecombinant B subunit cholera vaccine, 2 lots manufactured in June 1991 and February 1992 were tested in January 1995. Two oral doses of vaccine or placebo given 2 weeks apart were given with buffer to 216 Peruvian adults and children. Symptoms were elicited for 3 days after each dose. Serum and plasma specimens obtained from each volunteer before vaccination and 10- 14 days after the second dose were tested for vibriocidal and anti-cholera toxin antibodies. The vaccine was well- tolerated. Nearly half of the 100 vaccines had pre-vaccination vibriocidal titers greater than 140. Elevated titers were observed in 22 of 37 children 2-5 years of age compared with 66 of 63 vaccines 6-65 years P 0.001 A greater than 2-fold serum vibriocidal response was observed in 55 of 100 vaccines and 6 of 32 placebo recipients. An elevated pre- vaccination titer greater than 140 did not change the proportion of vaccines who responded with a greater than 2-fold increase in vibriocidal titer 51 versus 59, difference not significant, but did change the proportion responding with a greater than - fold increase 41 versus 22 P 0.05. The vibriocidal seroconversion rate was lowest in children 2-5 years old despite low pre-vaccination titers. Two-fold or greater serum antitoxic responses in IgA and IgG were observed in 90 of the vaccinees 4-fold responses were seen in 65-70 of the vaccinees with a 6-8-fold increase over baseline. Plasma specimens were as good as sera for determining anti-toxic antibodies by ELISA, but were less satisfactory for determining vibriocidal antibody titers.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research
  • Toxicology

Distribution Statement: